


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

“LINEZOLID TABLETS” OBTAINED DRUG REGISTRATION CERTIFICATE

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Linezolid Tablets” (trade name: Tian Li (天禮)), an anti-infective drug developed by the Group, has been granted drug registration certificate by the National Medical Products Administration of China and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.

Linezolid has a broad antibacterial spectrum and is effective against most clinically pathogenic Gram-positive (G+) bacteria and can be used to treat hospital-acquired pneumonia (HAP) caused by sensitive bacteria, complicated skin and skin soft tissue infections (including diabetic foot infections without osteomyelitis), uncomplicated skin and skin soft tissue infections, community-acquired pneumonia and associated bacteraemia, and infections caused by vancomycin-resistant *Enterococcus faecalis*.

Linezolid is a new type of oxazolidinone antibacterial drug with a unique mechanism of action, mainly inhibiting the protein synthesis of bacteria. With no cross-resistance to other antibacterial drugs, it has shown great advantages in the treatment of Gram-positive bacteria and tubercle bacillus infections and has a promising market application prospect.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 15 March 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.